Share price · PRTA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when PRTA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 9 Nov 2026+10.1%
Nothing announced by PRTA that day or the session before.
- 21 Oct 2026-5.5%
Nothing announced by PRTA that day or the session before.
- 7 Oct 2026+5.7%
Nothing announced by PRTA that day or the session before.
- 30 Sep 2026-4.6%
Nothing announced by PRTA that day or the session before.
- 24 Sep 2026-4.1%
Nothing announced by PRTA that day or the session before.
- 11 May 2026-9.9%
Nothing announced by PRTA that day or the session before.
- 28 Apr 2026+6.7%
Nothing announced by PRTA that day or the session before.
- 2 Mar 2026+8.4%
Share of unusual movement by asset
For each asset, the share of PRTA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Prasinezumabevents and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 2% |
| Other company news (earnings, financing, releases naming no asset) | — | 24% |
| Sessions with no dated event | — | 74% |
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | alpha-synucleinMonoclonal antibody | Parkinson's Disease | |
| Phase 2 | Tau (monoclonal antibody)Monoclonal antibody | Alzheimer's Disease |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
2029 (1)
June 2029 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0.6M | $8.4M | $272M | $17M-$12M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $1.0M | $8.8M | $289M | $19M-$25M operating cash flow | report ↗ |
| 2026-Q1 | $51M | — | $330M | — | report ↗ |
| 2025-Q3 | $2.4M | $29M | $332M | $37M-$41M operating cash flow | report ↗ |
| 2025-Q2 | $4.4M | $41M | $372M | $126M-$46M operating cash flow | report ↗ |
| 2025-Q1 | $2.8M | $51M | $419M | $60M-$53M operating cash flow | report ↗ |
| 2024-Q3 | $1.0M | $51M | $520M | $59M-$45M operating cash flow | report ↗ |
| 2024-Q2 | $132M | $58M | $565M | —$16M operating cash flow | report ↗ |
| 2024-Q1 | $0.1M | $64M | $549M | $72M-$73M operating cash flow | report ↗ |
| 2023-Q3 | $85M | $58M | $673M | —$9.5M operating cash flow | report ↗ |
| 2023-Q2 | $4.0M | $56M | $661M | $55M-$45M operating cash flow | report ↗ |
| 2023-Q1 | $2.2M | $45M | $688M | $47M-$47M operating cash flow | report ↗ |
| 2022-Q3 | $1.5M | $40M | $497M | $46M-$31M operating cash flow | report ↗ |
| 2022-Q2 | $1.3M | $32M | $510M | $41M-$35M operating cash flow | report ↗ |
| 2022-Q1 | $1.1M | $27M | $544M | $36M-$37M operating cash flow | report ↗ |
| 2021-Q3 | $139M | $18M | $601M | —$112M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $9.7M | $135M | $308M | $61M-$164M operating cash flow | report ↗ |
Prothena reported full-year 2025 revenue of $9.68M, down 92.8% YoY, with R&D spend of $134.85M, down 39.4% YoY. The company ended the year with $308.39M in cash and equivalents and reported a net loss of $244.09M.
For 2026, Prothena guided to full-year net cash used in operating and investing activities of $50–55M and approximately $255M ending cash at the midpoint, excluding potential milestone payments of up to $105M. Business highlights included partner Roche initiating the Phase 3 PARAISO trial for prasinezumab and Novo Nordisk initiating the Phase 3 CLEOPATTRA trial for coramitug, both with primary completion expected in 2029; Bristol Myers Squibb fully enrolling the Phase 2 TargetTau-1 trial for BMS-986446 and obtaining FDA Fast Track designation; and preclinical updates on TDP-43 CYTOPE and PRX012-TfR. Shareholders also approved a capital reduction to support a potential 2026 share redemption program.
Insider transactions
Open-market activity, trailing 12 months: 21 purchases ($13.7M), 2 sales ($136K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-17 | SCULLY WILLIAM P · 10% owner | Open-market purchase | 50,000 | $8.09 | $405K | Form 4 |
| 2026-11-09 | SCULLY WILLIAM P · 10% owner | Open-market purchase | 140,000 | $8.53 | $1.2M | Form 4 |
| 2026-11-06 | SCULLY WILLIAM P · 10% owner | Gift | 916,444 | — | — | Form 4 |
| 2026-10-27 | SCULLY WILLIAM P · 10% owner | Gift | 566,444 | — | — | Form 4 |
| 2026-10-23 | SCULLY WILLIAM P · 10% owner | Open-market purchase | 50,000 | $8.07 | $404K | Form 4 |
| 2026-10-22 | SCULLY WILLIAM P · 10% owner | Open-market purchase | 100,000 | $8.19 | $819K | Form 4 |
| 2026-10-14 | SCULLY WILLIAM P · 10% owner | Open-market purchase | 10,000 | $8.46 | $85K | Form 4 |
| 2026-10-13 | SCULLY WILLIAM P · 10% owner | Open-market purchase | 100,000 | $8.35 | $835K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 184 reporting institutions held 47.0M shares ($439.3M).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 7,551,218 | $73.4M |
| 2 | Rubric Capital Management LP | 5,000,000 | $48.6M |
| 3 | BlackRock, Inc. | 4,644,160 | $45.1M |
| 4 | STATE STREET CORP | 1,938,498 | $18.8M |
| 5 | D. E. Shaw & Co., Inc. | 1,763,347 | $17.1M |
| 6 | ADAR1 Capital Management, LLC | 1,581,443 | $15.4M |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,445,979 | $14.1M |
| 8 | MORGAN STANLEY | 1,230,448 | $12.0M |
| 9 | Palo Alto Investors LP | 1,208,568 | $11.7M |
| 10 | TWO SIGMA INVESTMENTS, LP | 1,205,978 | $11.7M |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 1,098,166 | $10.7M |
| 12 | FEDERATED HERMES, INC. | 1,059,849 | $10.3M |
| 13 | JACOBS LEVY EQUITY MANAGEMENT, INC | 972,017 | $9.4M |
| 14 | GOLDMAN SACHS GROUP INC | 818,885 | $8.0M |
| 15 | DIMENSIONAL FUND ADVISORS LP | 782,603 | $7.6M |